The Trump administration has made patient access to innovative treatments a critical priority and enjoyed great success with the "right to try" act and regulatory changes at the agency level.
Yet impediments to access remain as a result of bureaucratic drag, leaving some critical treatment options available for patients with private insurance at arm's length for Medicare patients.
